U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections) Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others), and By Place of Setting (Hospitals, Ambulatory Surgical Centers, and Office Based)

Published In : Oct 2023

Code : CMI4442

Pages :180

Formats :

Excel and PDF

Industry : Biotechnology

Market Challenges And Opportunities

U.S. Acellular Dermal Matrices Market - Drivers

Increasing number of surgeries: Increasing number of surgeries performed is expected to drive the growth of the U.S. acellular dermal matrices market over the forecast period. For instance, on September 21, 2023, according to data published by Cleveland Clinic, more than 1 million hernia surgeries are performed in the U.S. annually.
Increasing adoption of organic growth strategies such as product launch: Increasing adoption of organic growth strategies such as product launch by the key market players is expected to drive the growth of the U.S. acellular dermal matrices market over the forecast period. For instance, in November 2021, Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated in improving patient outcomes, launched two new innovative extracellular matrix products named- FORTIFY TRGT and FORTIFY FLOWABLE. FORTIFY FLOWABLE Extracellular Matrix is an advanced wound care device that presents the SIS ECM technology in a way that can fill irregular wound shapes and depths.

U.S. Acellular Dermal Matrices Market: Restraint

Complications of acellular dermal matrices in breast surgery: Complications of acellular dermal matrices in breast surgery and plastic surgery are expected to hamper the growth of the U.S. acellular dermal matrices market. For instance, in December 2021, according to data published, by National Library of Medicine, seroma, infection, mastectomy skin necrosis, and expander/implant loss were the most commonly reported complications with acellular dermal matrices. The most common complication found was necrosis/impaired healing.
Counterbalance: The key market players must focus in adopting launching of products which would not involve any sort of complications.